Search results
Results from the WOW.Com Content Network
[1] [2] Effects generally begin within half an hour and can last for up to a day. [1] Common side effects include nausea, diarrhea, low blood sugar, and headache. [1] Other side effects include sleepiness, skin rash, and shakiness. [3] The dose may need to be adjusted in those with liver or kidney disease. [1]
Sotagliflozin (Inpefa) is a dual SGLT1/SGLT2 inhibitor approved by the US Food and Drug Administration (FDA) in May 2023, to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes, chronic kidney disease, and other cardiovascular risk factors.
SGLT-2 has a role in regulation of glucose and is responsible for most glucose reabsorption in the kidneys. [1] [5] In diabetes, extracellular glucose concentration increases and this high glucose level leads to upregulation of SGLT-2, leading in turn to more absorption of glucose in the kidneys. These effects cause maintenance of hyperglycemia ...
Bexagliflozin may also cause serious side effects such as an increased incidence for surgery to remove parts of the legs or feet, decreases in blood pressure due to excessive loss of water and sodium from the body, serious infections in the genital region (Fournier’s gangrene), very low blood sugar levels when used in combination with insulin ...
Those included nausea and vomiting, kidney stones, gastroesophageal reflux disease (GERD), sleep issues, stomach cramps, pancreatitis, and gastroparesis (i.e. stomach paralysis).
It also reduced the risk of kidney failure and cut the risk of death from heart disease by about 5% in adults with both type 2 diabetes and chronic kidney disease, the company said in a news release.
Side effect may include low blood sugar, vomiting, abdominal pain, rash, and liver problems. [4] [7] Use by those with significant kidney problems or liver problems or who are pregnant is not recommended. [7] [4] Gliclazide is in the sulfonylurea family of medications. [7] It works mostly by increasing the release of insulin. [7]
Dapagliflozin is used along with diet, exercise, and usually with other glucose-lowering medications, to improve glycaemic control in adults with type 2 diabetes. . Dapagliflozin, in addition to other SGLT2-inhibitors, was shown to reduce the rate of decline in kidney function and kidney failure in non-diabetic and type 2 diabetic adults when added to the existing treatment